2024
ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.
Petrylak D, McKean M, Lang J, Gao X, Dreicer R, Geynisman D, Stewart T, Gandhi M, Appleman L, Dorff T, Chatta G, Tutrone R, De La Cerda J, Berghorn E, Gong J, Yu T, Dominy E, Chan E, Shore N. ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study. Journal Of Clinical Oncology 2024, 42: 5011-5011. DOI: 10.1200/jco.2024.42.16_suppl.5011.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerTreatment-related adverse eventsAR-LBD mutationsPhase 1/2 studyClinical activityProstate cancerAndrogen receptorAdverse eventsMetastatic castration-resistant prostate cancer treatmentProgressive metastatic castration-resistant prostate cancerPhase 1 dose-escalation portionDisease progressionTreatment-emergent adverse eventsCastration-resistant prostate cancerResistant to available therapiesAssociated with poor outcomesDose-limiting toxicityAndrogen deprivation therapyAdvanced prostate cancerIncreased blood creatinineWild-type ARSubgroup of patientsDose-dependent increaseDeprivation therapyPretreated patients
2018
TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
Ryan C, Abida W, Bryce A, Balar A, Dumbadze I, Given R, Morris D, Petrylak D, Redfern C, Scher H, Watkins S, Simmons A, Passler L, Golsorkhi T, Chowdhury S. TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). Journal Of Clinical Oncology 2018, 36: tps389-tps389. DOI: 10.1200/jco.2018.36.6_suppl.tps389.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerHomologous recombination deficiencyIndependent radiology reviewHomologous recombination (HR) DNA repair genesPhysician's choiceRadiology reviewDeleterious germlineProstate cancerRadiographic progression-free survivalCastration-resistant prostate cancerDNA repair genesObjective response rateProgression-free survivalPretreatment blood samplesAdvanced prostate cancerDuration of responsePatient-reported outcomesRepair genesMCRPC settingSecondary endpointsPrimary endpointRadiographic progressionOverall survivalComparator treatmentSomatic BRCA1TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
Abida W, Bryce A, Balar A, Chatta G, Dawson N, Guancial E, Hussain A, Jha G, Lipsitz D, Patnaik A, Petrylak D, Ryan C, Stanton T, Vogelzang N, Zhang J, Simmons A, Go J, Golsorkhi T, Chowdhury S, Scher H. TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). Journal Of Clinical Oncology 2018, 36: tps388-tps388. DOI: 10.1200/jco.2018.36.6_suppl.tps388.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerHomologous recombination deficiencyNodal diseaseDeleterious germlineProstate cancerProstate-specific antigen (PSA) responseRadiographic progression-free survivalCastration-resistant prostate cancerDNA repair genesClinical benefit rateObjective response ratePhase 2 studyPhase II studyProgression-free survivalTaxane-based chemotherapyHomologous recombination (HR) DNA repair genesPlatinum-based chemotherapyPretreatment blood samplesAdvanced prostate cancerDuration of responseSoft tissue diseaseRepair genesPrimary endpointSecondary endpointsII study
2007
Risk Factors for the Development of Bone Metastases in Prostate Cancer
Petrylak D. Risk Factors for the Development of Bone Metastases in Prostate Cancer. European Urology Open Science 2007, 6: 677-682. DOI: 10.1016/j.eursup.2007.03.005.Peer-Reviewed Original ResearchAndrogen deprivation therapyBone metastasesEarly prostate cancerProstate cancerRisk factorsEarly identificationDisease courseBone lossHigher baseline PSA levelsProstate-specific antigen levelChronic bone painHigh PSA velocityBaseline PSA levelsSpinal cord compressionMajority of patientsAdvanced prostate cancerBone health issuesBone health maintenanceBone mineral densityBone painCord compressionPalliative radiotherapyPSA velocitySkeletal complicationsPathologic fracture
2002
Chemotherapy for the Treatment of Hormone-Refractory Prostate Cancer
Petrylak D. Chemotherapy for the Treatment of Hormone-Refractory Prostate Cancer. European Urology Open Science 2002, 1: 15-23. DOI: 10.1016/s1569-9056(02)00005-2.Peer-Reviewed Original ResearchHormone-refractory prostate cancerBone painProstate cancerSerum prostate-specific antigen levelProstate-specific antigen levelPhase II trialPhase III trialsSoft tissue metastasesAndrogen ablation therapyEffective palliative therapyAdvanced prostate cancerCombination of mitoxantroneMetastatic prostate cancerTreatment of menHormonal therapyII trialIII trialsOverall survivalPalliative therapyPSA levelsTissue metastasesAntigen levelsTreatment optionsClinical trialsAblation therapy